- Home
- PMN vs MBRX Comparison
PMN vs MBRX Comparison
Compare PMN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- MBRX
- Stock Information
- Founded
- PMN 2004
- MBRX 2015
- Country
- PMN Canada
- MBRX United States
- Employees
- PMN N/A
- MBRX N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- PMN Health Care
- MBRX Health Care
- Exchange
- PMN Nasdaq
- MBRX Nasdaq
- Market Cap
- PMN 16.0M
- MBRX 12.9M
- IPO Year
- PMN N/A
- MBRX 2016
- Fundamental
- Price
- PMN $0.99
- MBRX $0.57
- Analyst Decision
- PMN Strong Buy
- MBRX Strong Buy
- Analyst Count
- PMN 3
- MBRX 3
- Target Price
- PMN $4.33
- MBRX $5.33
- AVG Volume (30 Days)
- PMN 21.0M
- MBRX 9.5M
- Earning Date
- PMN 08-07-2025
- MBRX 08-13-2025
- Dividend Yield
- PMN N/A
- MBRX N/A
- EPS Growth
- PMN N/A
- MBRX N/A
- EPS
- PMN N/A
- MBRX N/A
- Revenue
- PMN N/A
- MBRX N/A
- Revenue This Year
- PMN N/A
- MBRX N/A
- Revenue Next Year
- PMN N/A
- MBRX N/A
- P/E Ratio
- PMN N/A
- MBRX N/A
- Revenue Growth
- PMN N/A
- MBRX N/A
- 52 Week Low
- PMN $0.38
- MBRX $0.25
- 52 Week High
- PMN $2.05
- MBRX $3.67
- Technical
- Relative Strength Index (RSI)
- PMN 67.59
- MBRX 45.87
- Support Level
- PMN $0.77
- MBRX $0.74
- Resistance Level
- PMN $1.59
- MBRX $0.96
- Average True Range (ATR)
- PMN 0.19
- MBRX 0.13
- MACD
- PMN 0.06
- MBRX 0.02
- Stochastic Oscillator
- PMN 50.12
- MBRX 25.85
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.